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Abstract 
Purpose 
Metastatic gastrointestinal stromal tumor (GIST) is generally an incurable disease with 
variable response to imatinib. We aimed to develop prognostic nomograms to predict 
overall survival (OS) and progression-free survival (PFS) for patients treated with imatinib. 
Methods 
Nomograms were developed in a training cohort (n=330) of patients treated in a 
randomized trial (EORTC-ISG-AGITG 62005 phase III study) using Cox regression 
models, and validated in patients (n=236) treated in routine clinical care from six referral 
centers. Nomogram performance was assessed by calculating the c statistic. A classification 
based on the nomograms’ scores was generated to group patients according to risk. 
Results 
Nomogram risk factors for OS and PFS were size of the largest metastasis, tumor genotype, 
primary tumor mitotic count, hemoglobin, and blood neutrophil count at commencement of 
imatinib. The nomograms predicted survival with a c statistic of 0.75 (training) and 0.62 
(validation) for OS, and 0.69 (training) and 0.62 (validation) for PFS. When tested in the 
validation cohort, the nomograms discriminated well the high and intermediate risk from 
low risk patients (hazard ratio [HR] for OS 3.83, 95% confidence interval [CI] 1.71–8.56; 
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and 2.48, 95% CI 1.12–5.50; for PFS 2.84, 95% CI 1.66–4.87; and 1.45, 95% CI 0.87–2.41, 
respectively).  
Conclusion 
The nomograms predicted the risk of GIST progression and death with good discrimination 
of risk groups, and may be of value for patient counselling and risk stratification. 
 
Highlights: 
 Metastatic gastrointestinal stromal tumor has variable response to imatinib.  
 Nomograms developed using routinely available data are able to predict survival.  
 Nomograms may be of value for patient counselling and risk stratification. 
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Introduction 
Gastrointestinal stromal tumor (GIST) is a distinct subtype of sarcoma characterized 
commonly by mutations in the KIT and PDGFRA (encodes the platelet-derived growth 
factor receptor alpha) proto-oncogenes(1, 2). Although metastatic GIST is generally 
incurable, treatment with imatinib causes tumor regression or stabilization in the majority 
of patients, with a median overall survival (OS) of at least 5 years(3). However, assessment 
of the risk of cancer progression and death in an individual remains challenging, as GIST is 
a genetically heterogeneous disease and patient response to imatinib is variable(4). 
In patients with localized resectable GIST, risk of disease recurrence after surgery alone 
and in those who receive adjuvant imatinib can be estimated based on tumor size, mitotic 
activity, tumor location and rupture(5-8) but not tumor genotype(9, 10). Risk stratification 
schemes combining these prognostic factors have been developed to help quantify the 
likelihood of recurrence-free survival (RFS) and OS(11, 12).  
It is unclear whether stratification systems developed in a localized GIST population are 
applicable to patients with metastatic disease – a population with substantially poorer 
prognosis. Different factors may be important in the metastatic setting, for example, tumor 
genotype has been reported as having major prognostic significance in imatinib treated 
patients(13).  Tools to help classify risk of death and cancer progression in this population 
would be valuable for patient counseling and treatment decisions. For these reasons, we 
developed prognostic nomograms to group stratify and to provide individualized 
predictions of OS and progression-free survival (PFS) in these patients with metastatic 
GIST treated with imatinib. 
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Methods 
Patients 
We developed the nomograms using data from the ‘training’ cohort of a subset of patients 
who participated in the EORTC-ISG-AGITG 62005 phase III study comparing a daily dose 
of 400 mg versus 800 mg imatinib(14). These patients had metastatic GIST, and the KIT 
and PDGFRA genotype status were available(13). We validated the nomograms using data 
from the ‘validation’ cohort of patients undergoing routine clinical treatment for metastatic 
GIST at 6 large tertiary referral institutions in Warsaw, Helsinki, New York, Sydney, 
Melbourne and Canberra in 2000 to 2013. Patients included had metastatic GIST, 
histological confirmation of GIST diagnosis, known KIT genotype status, had received 
first-line therapy with imatinib for metastatic GIST, and did not participate in any first-line 
treatment clinical trials were included. The local institutional review board of each 
participating institution approved this study. 
Statistical methods 
We estimated OS and PFS probabilities using the Kaplan–Meier method(15). From the 
training cohort, we developed two multivariate models using Cox proportional hazards 
regression for OS and PFS outcomes, respectively. Each patient was assigned a score 
(scaled to range from 0 to 100) for each outcome; the score was based on the weighted sum 
of the relative importance of each variable in the multivariate models. We performed 
logarithmic transformation whenever appropriate for continuously measured variables with 
skewed distributions. The proportional hazards assumption was verified(16). All statistical 
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tests were two-sided, and P values less than .05 were considered to be statistically 
significant. 
A risk stratification scheme consisting of low-, intermediate-, and high-risk groups was 
developed based on the nomogram scores. This was done by grouping the scores from all 
patients into quartiles: the first quartile formed the low-risk (good-prognosis) group; the 
middle two quartiles were combined to form the intermediate-risk group; and the final 
quartile formed the high-risk (poor prognosis) group. 
We quantified the discriminatory ability of the nomograms in the training cohort by 
calculating the c statistic(17).  We also computed and compared the c statistics when the 
nomograms were applied to the validation dataset. We further illustrated the discriminatory 
ability of the nomogram-derived classification systems using Kaplan–Meier curves and log-
rank tests. 
The nomograms were also assessed for their calibration, which is a measure of how closely 
the predicted survival outcomes agree with the observed outcomes. We compared the 
nomogram-predicted probabilities for PFS at 1 and 2 years, and for OS at 3 years, with the 
corresponding observed PFS and OS probabilities. Plots that resemble a 45-degree line 
indicate that the nomogram predictions are well calibrated. We also computed the χ2 
statistic(18) to test for goodness-of-fit of the observed and predicted outcomes. A  P value 
<0.05 for this test indicates poor calibration of the model (that is, a significant difference 
between expected and observed outcomes).  
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We recalibrated the nomograms whenever there was systematic underestimation or 
overestimation of OS and PFS risks in the validation cohort. Recalibration allows the 
prediction function of the nomograms developed in a training cohort to be transportable to 
the validation cohort or other populations with different baseline risk.  
We performed sensitivity analyses to assess the performance of the nomograms when the 
following variables were excluded: tumor genotype, blood hemoglobin concentration, and 
blood neutrophil count. We further assessed the performance of the nomograms when 
tumor site was added as an additional variable.   
Results 
The training cohort consisted of 330 patients. The median follow-up was 34 months (range, 
0 to 43 months). A total of 216 patients (65%) had disease progression and 123 (37%) had 
died. The validation cohort consisted of 236 patients. The median follow-up was 70 months 
(range, 1 to 159 months). A total of 142 (60%) patients had disease progression and 107 
(45%) had died. Patients in the training cohort had significantly shorter OS than those in 
the validation cohort (median, OS 40.3 vs 66.7 months, respectively, P < .001) and shorter 
PFS (median, PFS 22.4 vs 34.0 months, P < .001; Figure 1). The baseline characteristics of 
patients are summarized in Table 1. Supplementary figure 1 shows the included and 
excluded patients in the training and validation cohorts. 
Nomogram for overall survival 
Figure 2A shows the nomogram to predict the probability of 3-year OS. A web-based 
version of this nomogram, Advanced GIST Online, is available at 
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http://advancedgistonline.ctc.usyd.edu.au  to provide individualized estimates of OS. The 
predictors were the longest diameter of the largest metastasis (millimetres, logarithmic 
scale), the absolute blood neutrophil count at imatinib initiation (x 10
9
/L, logarithmic 
scale), tumor genotype, blood hemoglobin concentration at imatinib initiation (g/dL), and 
the primary tumour mitotic count per 50 high-power fields (per 50 HPFs, logarithmic 
scale). All variables were statistically significant predictors in univariable and multivariable 
analyses (Supplementary Table 1). The c statistic value was 0.75 (95% CI, 0.71 to 0.80). 
Therefore, 75% of the time the nomogram correctly predicted the ordering of the outcome 
of two randomly selected patients.  
Figure 3A illustrates the good discriminatory value of the nomogram when the patients 
were stratified into low risk (nomogram score less than 32.67, n=84), intermediate risk 
(nomogram score 32.67 to 55.72, n=164), and high risk (nomogram score higher than 
55.72, n=82) prognostic groups (log-rank P < .001). When compared with the low-risk 
group, the high-risk group was associated with a 13.2-fold increase in risk of death (hazard 
ratio (HR) 13.22, 95% confidence interval (CI) 6.00 to 29.17), and in the intermediate-risk 
group, a 5.4-fold increase in risk of death (HR 5.43, 95% CI 2.48 to 11.86). 
When the nomogram was applied to the validation cohort, the c statistic was 0.62 (95% CI 
0.56 to 0.67). Figure 3B illustrates the discriminatory value of the nomogram when the 
patients in the validation cohort were stratified into three prognostic groups (log-rank P 
< .001). When compared with the low-risk group, the high-risk group was associated with a 
3.8-fold increase in risk of death (HR 3.83, 95% CI 1.71 to 8.56), and the intermediate-risk 
10 
 
group was associated with 2.5 fold increase in risk of death (HR 2.48, 95% CI 1.12 to 
5.50). 
Nomogram for progression-free survival 
Figure 2B shows the nomogram to predict the probabilities of 1-year and 2-year PFS. A 
web-based version of this nomogram is available at 
http://advancedgistonline.ctc.usyd.edu.au to provide individualized estimates of PFS. In 
multivariable analyses (Supplementary Table 1), the same predictors for OS were also 
significant predictors of PFS except for size of the largest metastasis. Although it was not 
statistically significant (P = .11), size of the largest metastasis was considered to be a 
clinically relevant variable and was reintroduced into the model. The c statistic was 0.69 
(95% CI 0.65 to 0.73).  
Figure 3C illustrates the discriminatory value of the nomogram when patients were 
stratified into low-risk (nomogram score less than 27.54, n=83), intermediate-risk 
(nomogram score 27.54 to 56.30, n=165), and high-risk (nomogram score greater than 
56.30, n=82) prognostic groups (log-rank P < .001). When compared with the low-risk 
group, the high-risk group was associated with a 4.8-fold increase in risk of disease 
progression or death (HR 4.75, 95% CI 3.15 to 7.21), and the intermediate-risk group with 
2.3-fold increase in risk of disease progression or death (HR 2.30, 95% CI 1.55 to 3.39). 
When the nomogram was applied to the validation cohort, the c statistic was 0.62 (95% CI 
0.58 to 0.68). Figure 3D illustrates the discriminatory value of the nomogram when the 
patients in the validation cohort were stratified by prognosis groups (log-rank P < .0001). 
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When compared with the low-risk group, the high-risk group was associated with a 2.8-fold 
increase in risk of disease progression or death (HR 2.84, 95% CI 1.66 to 4.87), and the 
intermediate-risk group with a 1.5-fold increase in risk of disease progression or death (HR 
1.45, 95% CI 0.87 to 2.41). 
Supplementary Table 2 also summarised the univariable analyses of all other variables 
considered but were not included in the final multivariable models for OS and PFS.   
Calibration 
When the nomograms were applied to the validation cohort, the predicted OS and PFS 
systematically underestimated the observed survival outcomes. Recalibration with 
multiplication with a single scaling factor (0.547 for OS and 0.739 for PFS) on all the 
regression coefficients substantially improved the performance of the nomograms in the 
validation cohort (Figure 4). The predicted probabilities of OS and PFS illustrated in Figure 
2 and on the website (http://advancedgistonline.ctc.usyd.edu.au) have been scaled to better 
represent patients in routine care.  
Sensitivity analyses 
When tumor genotype was excluded in the multivariable models, the performance of the 
models was significantly poorer (Supplementary Table 3). Exclusions of blood hemoglobin 
concentration and the blood neutrophil count also reduced the performance of the 
multivariable models. Inclusion of the primary tumor site did not improve the models 
significantly.  
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Discussion 
The nomograms were developed as pragmatic tools that combine readily available clinical 
information to provide rapid and simple prognostic information from otherwise complex 
statistical estimates. To our knowledge, this study provides the first prognostic 
classification for metastatic GIST patients treated initially with imatinib. 
Despite differences in the baseline characteristics in the training and validation cohorts 
(Table 1), the prognostic nomograms provided good discrimination for OS (c statistic 0.75 
and 0.62, respectively) and PFS (c statistic 0.69 and 0.62, respectively) in both cohorts. 
Similarly, there is also good discrimination of survival outcomes based on a classification 
system of low, intermediate and high risk (Figure 3).  
Recalibration was necessary when the nomograms were applied to the validation cohort as 
the patients had significantly longer median OS and PFS times than the training cohort. At 
the time when the EORTC-ISG-AGITG 62005 study was initiated, there was no effective 
systemic therapy for advanced GIST, and hence patients enrolled in that trial likely had 
more advanced disease with a greater tumor bulk than most current patients. The validation 
cohort, on the other hand, includes patients with more recent diagnoses and access to 
multiple lines of tyrosine kinase inhibitors. The differences between these two populations 
probably accounted for the lower c statistics observed in the validation cohort. The 
systematic underestimation of the survival in the validation cohort was hence recalibrated 
with a single simple scaling factor on the weights (regression coefficients) of the individual 
factors in the nomograms. Notably the calibration process does not affect hazard ratio 
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comparisons and hence does not affect the discrimination performance. OS times likely will 
continue to improve with increasing therapeutic options and earlier detection of advanced 
disease by improved imaging modalities. Using this recalibration process with future 
patient cohort data may allow the nomograms to remain contemporary. 
These nomograms identified predictors of survival in metastatic patients treated with 
imatinib, distinct from those with localized GIST. Tumor genotype has a major impact in 
the metastatic population, but evidence remains conflicting in localized GIST even with 
adjuvant imatinib(9, 10). This may partly relate to use of 400 mg imatinib in an adjuvant 
study where there might be poorer outcomes in those with exon 9 KIT mutations(13). On 
the other hand, tumor site has minimal effect in metastatic GIST (Supplementary Table 3), 
in contrast to its large impact on prognosis in localized GIST(8). Although not a 
statistically significant variable, size of the largest metastasis was included in the PFS 
nomogram as it is widely regarded as an important prognostic factor.  
Nomograms offer an alternative to current practice, where estimates of prognosis rely on 
individual clinician experience or published median survival times. Another popular 
alternative would be to use single prognostic factors, such as GIST tumor genotype, or a 
simple summation of factors to predict good versus poor outcomes. This latter approach 
fails to account for interactions and assumes that all prognostic factors are of equal weight, 
potentially underestimating survival outcomes(19). Nomograms provide more accurate 
estimates by combining clinical predictors into single summary measures. Our online 
nomogram can also be used to communicate the level of uncertainty surrounding individual 
estimates of survival outcomes for the typical (half to double the median survival), best-
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case (triple the median), and worst-case (one quarter of the median) scenarios using the 
approach developed for use in advanced breast cancer(20). In addition to providing 
improved prognostic information for counselling, they also have a role in guiding clinical 
follow-up assessment frequency based on risk of relapse, and to stratify future patients for 
clinical trials especially if adaptive strategies based on prognostic factors are being 
investigated. 
This study has several strengths. The nomograms utilised variables that are widely 
available in clinical practice. Their performance has been assessed in an independent 
dataset of patients undergoing routine clinical treatment for metastatic GIST from 
institutions located in five different countries. There are also potential limitations. The 
predictive ability of the nomograms (c statistic of 0.62 in validation dataset for PFS and 
OS) remains modest and further work is required to identify other factors that impact on 
survival. The assessment of mitotic count was variable and not standardized(21). 
Furthermore, we have examined mitotic count using the standard per 50 HPFs instead of 
the recent recommendation of number of mitoses on a total area of 5 mm
2
(22) as 
comparative data of whether this new approach will improve prediction accuracy remains 
limited. We have also not looked for all possible prognostic factors in metastatic GIST such 
as gene expression profiling(23).  Despite these limitations, the present nomograms 
represent a useful advancement, and could act as a platform to incorporate new prognostic 
factors as our understanding of the biology of GIST progresses and new treatment 
strategies emerge. 
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In summary, the nomograms developed in a clinical trial population predicted the risk of 
GIST progression and death with good discrimination of risk groups in routine-care 
populations. This work also generates new risk stratification schemes for patients with 
metastatic GIST treated with imatinib.  
 
Conflict of interest statement  
The authors declared no conflicts of interest in relation to this work. 
Acknowledgment 
The authors acknowledge the editorial support provided by Rhana Pike (NHMRC Clinical 
Trials Centre). The authors also thank the European Organization for Research and 
Treatment of Cancer for permission to use the data from EORTC study 62005 for this 
research. The contents of this publication and methods used are solely the responsibility of 
the authors and do not necessarily represent the official views of the EORTC Headquarters.  
 
 
  
Table 1: Baseline patient characteristics and clinicopathological variables 
 
Characteristic 
Training cohort 
N=330 
Validation cohort 
N=236 P* 
Median age (range) (years) 61 (18–84) 56  (17–87) .004 
Sex    
 Male 206 (62) 133 (56) .15 
 Female 124 (38) 103 (44)  
Primary site of the disease    
 Stomach 108 (39) 83 (36) <.001 
 Small bowel 84 (30) 115 (49)  
 Duodenum 35 (13) 3 (1)  
 Omentum 13 (5) 1 (<1)  
 Rectum 18 (6) 4 (2)  
 Colon 10 (4) 13 (5)  
 Other 62(19) 16 (7)  
 Unknown 0 (0) 1 (<1)  
Median time, primary diagnosis to initiation of 
imatinib (range) (month) 
11.3 (0–208) 6 (0–286) .001  
Imatinib starting dose  (mg)    
 200 0 (0) 1 (<1) <.001 
 300 0 (0) 9 (4)  
 400 160 (48) 207 (88)  
 600 0 (0) 7 (3)  
 800 170 (52) 9 (4)  
Median size of largest metastasis (mm) (range) 80 (10–306) 80 (10–350) .20  
Median primary tumour mitotic count (range)† 5 (1–62) 20 (1–250) <.001  
GIST genotype    
 KIT exon 11 208 (63) 161 (68) .29 
 KIT exon 9 52 (16) 30 (13)  
 Wild-type 51 (15) 27 (11)  
 Other 19 (6) 18 (8)  
Median blood neutrophil count (range) (x 10
9
 / L) 4.9 (1.5–30.6) 4.3 (1.1–15.7) .001  
Median blood hemoglobin (range) (g/dL) 12.7 (7.6–17.6) 12.8 (6.4–16.3) .70 
 
Data are number (%) or median (range).  
* P for differences in distributions between training and validation cohorts. 
† Mitotic count = number of mitoses per 50 high-power fields of the microscope. Other tumor genotypes include 
KIT exon 13 (n=7), KIT exon 17 (n=3), PDGFRA mutations (n= 9) in the training cohort. Other tumor 
genotypes in the validation cohort include KIT exon 13 (n=5), KIT exon 18 (n=1), KIT exon 17 (n=1), PDGFRA 
mutations (n=11) 
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Figure Legends 
Figure 1 Overall survival and progression-free survival in the training and 
validation cohorts 
Kaplan-Meier estimates of overall survival and progression-free survival of patients with 
metastatic GIST treated with imatinib in the EORTC-ISG-AGITG phase III study (training 
cohort) and in routine clinical care from six institutions (validation cohort). OS=overall 
survival. PFS=progression-free survival. 
Figure 2 Nomograms to predict the probabilities of 3-year overall survival, and 
1-year and 2-year progression-free survival 
Points are assigned for largest tumor size, blood neutrophil count, tumor genotype, blood 
hemoglobin, and tumor mitotic count, by drawing a line upward from the corresponding 
values to the “Points” line. The sum of these 5 points, plotted on the “Total points” line, 
corresponds to predictions of (A) probability of 3-year overall survival (OS) and median 
overall survival, and (B) probability of 1-year progression-free survival (PFS) and 2-year 
PFS, and median PFS.  
*Largest metastasis, neutrophils and mitotic count are measured on a logarithmic scale 
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Figure 3 Overall survival and progression-free survival of training and 
validation cohorts according to risk groups 
Kaplan-Meier estimates according to low-, intermediate- and high-risk groups of metastatic 
GIST patients treated with imatinib, based on subset of patients enrolled in the (A) training 
cohort and (B) validation cohort for overall survival, and (C) training cohort and (D) 
validation cohort for progression-free survival. 
 
Figure 4: Calibration of nomogram-predicted overall survival and progression-free 
survival 
Observed overall survival compared with nomogram-predicted at 3 years (A) uncalibrated 
and (B) recalibrated plot for the validation cohort.  Observed progression-free survival 
compared with nomogram-predicted survival at 2 years (C) uncalibrated and (D) 
recalibrated plot for the validation cohort. OS=overall survival. PFS=progression-free 
survival. 
A significant goodness-of-fit P value (P < .05) indicates lack of calibration of the model. 
 
22 
 
Supplementary Figure 1: Flow diagram of included and excluded patients in the 
training and validation cohorts 
 
 
Table Legend 
Table 1 Baseline patient characteristics and clinicopathological variables 
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